Plasma microRNA signature associated with retinopathy in patients with type 2 diabetes

D. Santovito, L. Toto, V. De Nardis, P. Marcantonio, R. D'Aloisio, A. Mastropasqua, D. De Cesare, M. Bucci, C. Paganelli, L. Natarelli, C. Weber, A. Consoli, R. Mastropasqua*, F. Cipollone*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Web of Science)


Diabetic retinopathy (DR) is a leading cause of vision loss and disability. Effective management of DR depends on prompt treatment and would benefit from biomarkers for screening and pre-symptomatic detection of retinopathy in diabetic patients. MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression which are released in the bloodstream and may serve as biomarkers. Little is known on circulating miRNAs in patients with type 2 diabetes (T2DM) and DR. Here we show that DR is associated with higher circulating miR-25-3p (P=0.004) and miR-320b (P=0.011) and lower levels of miR-495-3p (P<0.001) in a cohort of patients with T2DM with DR (n=20), compared with diabetic subjects without DR (n=10) and healthy individuals (n=10). These associations persisted significant after adjustment for age, gender, and HbA1c. The circulating levels of these miRNAs correlated with severity of the disease and their concomitant evaluation showed high accuracy for identifying DR (AUROC=0.93; P<0.001). Gene ontology analysis of validated targets revealed enrichment in pathways such as regulation of metabolic process (P=1.5x10(-20)), of cell response to stress (P=1.9x10(-14)), and development of blood vessels (P=2.7x10(-14)). Pending external validation, we anticipate that these miRNAs may serve as putative disease biomarkers and highlight novel molecular targets for improving care of patients with diabetic retinopathy.
Original languageEnglish
Article number4136
Number of pages8
JournalScientific Reports
Issue number1
Publication statusPublished - 18 Feb 2021

Cite this